invivodata was included on Pittsburgh Business Times’ “Pittsburgh 100” list of the region’s fastest-growing private companies. Honored at an awards program at the Duquesne Club in downtown Pittsburgh on August 21, invivodata was ranked the tenth fastest-growing technology company and number 43 overall on the list of 100, based on revenue growth. Rankings on the list were based on the rate of growth from 2005 through 2007. 

Bio-Imaging Technologies said its president and CEO, Mark Weinstein, is scheduled to present at the 11th Annual Investor Conference organized by Kaufman Bros, a research-based, full-service investment bank, securities trading firm and brokerage operation provider, at 9:00 a.m. EDT on September 5, 2008. Here’s the release.

ICD Global launched an online catalog for promotional items for patients and sites in clinical trials. IT lists 300,000 customizable items. ICD Global’s website will store and ship items. The company integrates catalog orders into TrialVision, its online materials management program, which allows users to track promotional items and printed materials.

MDS Pharma Services hired Ross Tonkens to provide medical oversight for Phase IIa clinical research activities and to direct the medical and clinical activities of its development and regulatory services. As VP of medical affairs, Tonkens will design clinical study protocols, provide medical consultation to clients, and chair the company’s development and regulatory services medical advisory board. Said MDS Pharma Services president David Spaight: “We’re proud to offer our clients access to the caliber of medical expertise possessed by Dr. Tonkens. His experience spans academia, biotechnology and the contract research organization industry.” Here’s the release.

Algorithme Pharma has followed up its acquisition of a clinical research center in Baltimore, Maryland, last month by taking over Simbec Research, an early-phase specialist in Wales, UK. No financial details were disclosed.  “Given the considerable growth of our international clientele, it became necessary to acquire a location in Europe in order to better serve our fast-growing market once we had expanded to the United States,” explained president and CEO Louis Caillé.

Tessella’s getting ready to release an adaptive trials simulation program. It says it will be the first opportunity for most sponsor companies to interact directly with a Bayesian design from Berry Consultants. “The simulator is built around a flexible core design developed by the statistical consultancy and ready for deployment, out of the box,” says Tom Parke, head of clinical trials solutions at Tessella. “The software will need only a few minor tweaks by Berry Consultants before it can be used to make adaptations.” The adaptive trials simulator will launch commercially in the fourth quarter of 2008. Three top ten pharmaceutical companies are already actively working with Tessella in a handful of dose-finding ACTs designed by Berry Consultants. Here’s an article.

Have a news release? Send it to .